REPROCELL Launches Hypoimmune iPSC Lines Using Proprietary Genome Editing Technology
- kelseygarbutt
- 3 days ago
- 1 min read
NETPark-based REPROCELL has launched new StemEdit™ Human iPSC lines designed to reduce immune rejection in cell therapies.
These hypoimmune cells are engineered using REPROCELL’s proprietary StemEdit™ platform, which enables high-efficiency knockout of HLA Class I and II genes.
The new lines—B2M KO and B2M/CIITA double KO—are derived from REPROCELL’s clinical-grade iPSCs and are ideal for immune research and regenerative medicine. Available for research use, they also come with licensing options for clinical applications.
This innovation highlights REPROCELL’s leadership in stem cell technology and the cutting-edge biotech ecosystem at NETPark.
